Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

What’s Next? Five Things To Look Out For In January

A third biosimilar to Genentech’s Rituxan is set to hit the US this month, as players begin to publish full-year financial results encompassing a remarkable year.

Generic Drugs Biosimilars

Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite

Japan’s Nichi-Iko saw its bottom line take a hammering in the six months to 30 September, as a number of its products had their prices cut following revisions to the National Health Insurance program.

Sales & Earnings Strategy

Nippon Chemiphar Struggles Despite New Launches

Nippon Chemiphar saw its overall sales drop by 7.9%, dragged down by a fall in generics sales of 9.7%, in its financial first half ended 30 September 2020. The Japanese company’s plan to ride on the success of new launches faltered as it was unable to compensate for the impact of NHI drug price revisions implemented in October 2019 and again in April 2020. 

Sales & Earnings Japan

Indoco Counts On Indian Market Bouncing Back

Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump.  The Indian company continues to perform well internationally and grow overall.

Sales & Earnings India

Sandoz Aims For $6bn Biosimilar Business By 2030

Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.

Biosimilars Strategy
See All
UsernamePublicRestriction

Register